DDInter1763 DDInter1578
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues. Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola.[A191379, A222393] Broad antiviral activity of remdesivir is suggested by its mechanism of action, and to date, it has demonstrated _in vitro_ activity against the _Arenaviridae_, _Flaviviridae_, _Filoviridae_, _Paramyxoviridae_, _Pneumoviridae_, and _Coronaviridae_ viral families. Remdesivir activity against the _Coronaviridae_ family was first demonstrated in 2017, leading to considerable interest in remdesivir as a possible treatment for COVID-19.[A191427, A198810] Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV, and has been investigated in multiple COVID-19 clinical trials.[L12174, L12177] After initially being granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020, remdesivir was fully approved by the FDA for the treatment of COVID-19 on October 22, 2020. Remdesivir is currently marketed under the trademark name VEKLURY by Gilead Sciences Inc. Remdesivir was also approved by the European Commission on July 3, 2020. Remdesivir in combination with [baricitinib] for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on November 19, 2020.
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Temsirolimus {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Pioglitazone
Pioglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pioglitazone
Pioglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Temsirolimus {u} (Compound) upregulates {v} (Gene) MYC
MYC {u} (Gene) is upregulated by {v} (Compound) Pioglitazone
Pioglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Diclofenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Temsirolimus {u} (Compound) causes {v} (Side Effect) Anaphylactic shock
Anaphylactic shock {u} (Side Effect) is caused by {v} (Compound) Pioglitazone
Pioglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Temsirolimus {u} (Compound) upregulates {v} (Gene) MYC
MYC {u} (Gene) is downregulated by {v} (Compound) Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Temsirolimus {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Hydroxychloroquine
Hydroxychloroquine {u} may lead to a major life threatening interaction when taken with {v} Remdesivir
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Temsirolimus (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pioglitazone (Compound) and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Temsirolimus (Compound) upregulates MYC (Gene) and MYC (Gene) is upregulated by Pioglitazone (Compound) and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Temsirolimus (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Pioglitazone (Compound) and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Temsirolimus (Compound) upregulates MYC (Gene) and MYC (Gene) is downregulated by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Temsirolimus (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound) and Hydroxychloroquine may lead to a major life threatening interaction when taken with Remdesivir